AbbVie's weak newer drug sales fan worries as Humira faces rivals

AbbVie Inc on Thursday missed quarterly revenue estimates for its newer treatments, fueling concerns over the drugmaker's attempts to cushion the blow to sales from fresh competition for its flagship arthritis drug Humira.

Related Keywords

Bengaluru ,Karnataka ,India ,Sriraj Kalluvila ,Evan Seigerman ,Leroy Leo ,Abbvie Inc ,Thomson Reuters Trust Principles ,Allergan ,Reuters ,Amgen Inc ,Vie Inc ,Botox Maker Allergan ,Mariame Sunny ,Thomson Reuters Trust ,Rhpi Commercial Strategy ,Rhpi Drug Device Trials ,Mtpix ,Bact ,Biz ,Blr ,Cmpny ,Cprod ,Drudev ,Gen ,Genhlt ,Hea ,Headmi ,Heca ,Humdis ,Mrch ,Painmg ,Phag08 ,Phar ,Phar08 ,Phar1 ,Phmr ,Publ ,Pxp ,Pres ,Resf ,Rheuma ,Sci ,Gamers ,Us ,Namer ,Topnws ,Shot ,Stx ,Topcmb ,Privt ,Ceeu ,Europ ,Cz ,Emrg ,